Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open-label, Multicenter Effectiveness and Safety Observational Study of Zemplar in Patients With Stage 5 Chronic Kidney Disease and Hyperparathyroidism on Hemodialysis in the Russian Federation

NCT01401478 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT01401478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01401478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open-label, Multicenter Effectiveness and Safety Observational Study of Zemplar in Patients With Stage 5 Chronic Kidney Disease and Hyperparathyroidism on Hemodialysis in the Russian Federation
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Observational
Overall status
Completed
Start date
July 31, 2011
Completion date
January 31, 2013
Enrollment
86 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

secondary hyperparathyroidism